石四藥集團(02005.HK)一家國內著名製藥公司簽訂合作意向書 擬委託生產布洛芬緩釋片等
格隆匯12月18日丨石四藥集團(02005.HK)發佈公吿,集團全資附屬公司石家莊四藥有限公司於2022年12月17日與一家國內著名製藥公司簽訂了一份合作意向書。根據該意向書,委託方擬委託石家莊四藥生產布洛芬緩釋片及小兒氨酚黃那敏顆粒,委託生產量分別為每年10億至25億片及每年6500萬袋。
該委託生產使用包括布洛芬、對乙醯氨基酚、人工硫磺及馬來酸氯苯那敏的原料藥由委託方採購,其費用由委託方承擔。除原料藥以外委託生產所需的輔料、包裝材料、生產相關的各類費用及運輸費用均包含在雙方約定的委託生產加工費中。根據早前國務院聯防聯控機制發佈的新冠病毒感染者居家治療常用藥參考表,布洛芬及對乙醯氨基酚入選發熱症狀常用藥物。公司預期該委託生產將為集團的相關業務帶來突破性增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.